Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMP014/ALFQ Malaria Vaccine Phase 1 with CHMI
NCT04296279Phase 1Unknown
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FMP014 in malaria (6 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Safety Dosage of Candidate Malaria Vaccine FMP014/ALFQ at 393 Days and Assess expected immunological response associated with Candidate Malaria Vaccine FMP014/ALFQ at 393 Days. Status: unknown.
02
Drugs
FMP014
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04296279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296279.